Aging
Navigate
Research Paper|Volume 13, Issue 8|pp 11752—11761

5-Lipoxygenase inhibition reduces inflammation and neuronal apoptosis via AKT signaling after subarachnoid hemorrhage in rats

Liu Liu1, Ping Zhang2, Zhaosi Zhang3, Yidan Liang1, Hong Chen2, Zhaohui He2, Xiaochuan Sun2, Zongduo Guo2, Yongbing Deng1
  • 1Department of Neurosurgery, Chongqing Emergency Center, Chongqing University Center Hospital, School of Medicine, Chongqing University, Chongqing, China
  • 2Department of Neurosurgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
  • 3Department of Cerebrovascular Diseases, The First Affiliated Hospital of Zunyi Medical University, Guizhou, China
Received: November 24, 2020Accepted: March 14, 2021Published: April 20, 2021

Copyright: © 2021 Liu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Early brain injury (EBI) is a major contributor to the high mortality and morbidity after subarachnoid hemorrhage (SAH). Inflammatory responses and neuronal apoptosis are important causes of EBI. Because 5- lipoxygenase (5-LOX) is known to be involved various central nervous system diseases, we investigated the effects of 5-LOX inhibition during EBI after SAH. Zileuton and LY294002 were used to inhibit expression of 5-LOX and Akt, respectively. We found that 5-LOX expression was significantly increased in the cytoplasm of cortical neurons after SAH and was accompanied by upregulated expression of the inflammatory factors LTB4, TNF-α, IL-1β and IL-6; upregulation of the pro-apoptotic factor Bax; downregulation of the anti-apoptotic factor Bcl-2; and an increased apoptosis rate. Gastric Zileuton administration significantly suppressed all of those effects and improved neurological function. Zileuton also upregulated activated (phosphorylated) AKT levels, and these beneficial effects of Zileuton were abolished by intracerebroventricular infusion of the PI3K inhibitor LY294002. Taken together, these findings indicate that 5-LOX mediates pro-inflammatory and pro-apoptotic effects that contribute to EBI after SAH and that those effects are suppressed by activation of PI3K/Akt signaling. This suggests targeting 5-LOX may be an effective approach to treating EBI after SAH.